Ryan Long of Paragon Health Institute said most 340B revenue goes to large hospital systems instead of struggling hospitals and called for reforms targeting spread gaming. Read More »
West Cuthbert of American Resolve Action urged congressional Republicans on May 4 to back efforts by the Trump administration aimed at increasing transparency in the federal 340B Drug Pricing Program through a rebate-based pilot. Read More »
The Wall Street Journal Editorial Board highlighted a federal court decision blocking North Dakota’s 340B law on May 7. Read More »
Sally Pipes of Pacific Research Institute said President Trump is pushing for greater transparency in the federal 340B drug discount program amid resistance from hospital lobbyists. Read More »
Chase Martin of August Strategy Group called for Republican support for reforms targeting hospital practices under the federal 340B Drug Pricing Program. Read More »
PhRMA has called for increased congressional scrutiny of the federal 340B drug pricing program due to concerns about rapid expansion and insufficient oversight. Read More »
Shawn Gremminger of the National Alliance Of Healthcare Purchaser Coalitions called for reforms to New York's participation in the federal 340B Drug Pricing Program due to concerns over cost increases and lack of accountability. Read More »
In 2025, three major pharmacy benefit managers controlled about 80% of US prescription claims according to an analysis by the Drug Channels Institute. Read More »
A new survey by the Biotechnology Innovation Organization finds strong voter support for reforms increasing transparency in the federal 340B drug pricing program. Read More »
Garrina Ross of Tigerlily Foundation called for reforms to ensure that savings from the federal 340B drug-pricing program reach vulnerable patients rather than being absorbed elsewhere. Read More »
Frier Levitt warned that some pharmacy benefit managers are placing hospital pharmacies into lower-reimbursement networks they say may be unlawful. Read More »
Dutch Rojas of Bliksem Health criticized pharmacy benefit manager (PBM) dominance in U.S. prescription drug distribution. Read More »
Molly Jenkins of PhRMA said increased scrutiny of the federal 340B drug pricing program highlights concerns about rising costs without clear patient benefits. Read More »
Building America’s Future claims a lobbying group is blocking reforms aimed at increasing transparency in the federal drug discount program known as 340B. Read More »
Mark Cuban says new rules targeting pharmacy benefit managers will not shift pricing power away from industry leaders controlling drug rebates. Recent reports highlight continued market dominance by three major PBMs despite regulatory efforts. Experts point to rebate structures as a key factor affecting patient costs. Read More »
Congressional bill H.R. 7148 has been signed into law by the White House, introducing reforms targeting pharmacy benefit manager practices in Medicare Part D. The legislation aims to shift compensation structures away from rebate-linked incentives... Read More »
U.S. Representative Raja Krishnamoorthi advocates for a bipartisan bill aimed at reforming pharmacy benefit manager practices that allegedly inflate drug prices. Read More »
The article discusses concerns about the effectiveness of the expanding 340B drug discount program originally designed for low-income patient support but now criticized for benefiting providers more than patients directly due to spread pricing... Read More »
Matt Wallace highlights concerns about pharmacy benefit managers' practices affecting rural areas. Read More »
The article discusses concerns regarding hospital profits from discounted cancer drugs under the federal 340B program. Read More »
Alerts Sign-up
